25 results about "Peptide fragment" patented technology

This invention relates to the fields of molecular biology and biomedicine, disclosing plasma-active peptides with antithrombotic effects and their uses. The invention obtains various active peptides from plasma through screening and solid-phase synthesis, and confirms their biological activity through in vitro platelet aggregation experiments and in vivo arterial thrombosis model experiments. Results show that peptides 1957, 1960, and 1961 significantly inhibit collagen-induced platelet aggregation, exhibiting good antiplatelet activity; animal experiments show that peptides 1955, 1957, 1960, and 1961 significantly inhibit arterial thrombosis. These active peptides are derived from endogenous plasma components, belonging to natural antithrombotic substances, possessing good physiological compatibility and safety advantages, and reducing the risk of immunogenicity and adverse reactions. These peptides can exert antithrombotic effects without relying on traditional antiplatelet drugs, providing a new source of active molecules and treatment options for the prevention and treatment of thrombotic diseases.

Provided is a bispecific antibody targeting CD3 and a tumor target and a use of the bispecific antibody. The bispecific antibody comprises a first antigen binding region, a second antigen binding region, and an Fc portion; the Fc portion comprises a first Fc peptide fragment and a second Fc peptide fragment; the first antigen binding region comprises an scFv fragment and a binding protein or fragment thereof of a first molecule, the binding protein or fragment thereof of the first molecule is linked to the N-terminal of the scFv fragment, and the C-terminal of the scFv fragment is linked to the N-terminal of the first Fc peptide fragment; the second antigen binding region comprises a binding protein or fragment thereof of a second molecule; and the first molecule and the second molecule are the identical, and the scFv fragment has CD3 binding activity.

The present disclosure is drawn to an endolysin protein against Streptococcus pneumoniae (Spn), designated SP-CHAP. The disclosure provides methods of treating diseases in a subject resulting from infection with pneumococcal bacteria, said diseases including but not limited to pneumonia, invasive pneumococcal disease, meningitis and sepsis. Such treatment methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising SP-CHAP polypeptide, polypeptide fragments, SP-CHAP encoding nucleic acids (RNA / DNA) or variants thereof.

This invention discloses an antioxidant active peptide derived from Litsea cubeba, its preparation method, and its application, relating to the field of biotechnology. The amino acid sequence of this Litsea cubeba-derived antioxidant active peptide is NPYYFWDLSF. The preparation method of this Litsea cubeba-derived antioxidant active peptide includes the following steps: S1, extracting Litsea cubeba protein from Litsea cubeba seed cake; S2, enzymatically hydrolyzing the Litsea cubeba protein using acidic protease to obtain the enzymatic hydrolysis product; S3, separating the enzymatic hydrolysis product by ultrafiltration and collecting the ultrafiltration fraction; S4, screening candidate peptides with high antioxidant activity from the peptide fragments of the ultrafiltration fraction; the application of the Litsea cubeba-derived antioxidant active peptide in the preparation of drugs or functional foods for the prevention or treatment of oxidative stress-related diseases; the NPYYFWDLSF peptide obtained by the preparation method of this application can alleviate oxidative stress damage through the PI3K-AKT signaling pathway; this application provides a theoretical basis for the high-value utilization and potential application of Litsea cubeba by-products.

This invention provides a simple method for evaluating whether or not a peptide binds to isovaleric acid. [Solution] A method for evaluating the binding affinity to isovaleric acid, comprising a preparation step of preparing a fluorescently labeled compound in which a fluorescent group is bonded to the α-carbon atom of isovaleric acid, and a contact step of contacting the fluorescently labeled compound with a peptide fragment of an olfactory receptor.

This invention relates to a fractured solid-phase alkylation material, its preparation, and its application. Using epoxy-based microspheres as a carrier, polyethyleneimine, an acid-fractureable linker arm, and iodoacetic acid-N-succinamide ester are sequentially modified via covalent bonding to prepare the fractured solid-phase alkylation material. This material selectively reacts with thiol groups on proteins, enabling efficient enrichment and processing of proteins in complex biological samples such as cells, tissues, and body fluids. By cleaving the linker arm under acidic conditions, the protein and peptide fragments can be released without damage, potentially providing important technical support for deep proteomic coverage analysis and protein variant analysis.

The present application relates to methods for quantifying citrullination and methods that can be used to assess the activity of agents, including, for example, PAD4 (peptidyl arginine deiminase 4) modulators, such as small molecules or antibodies. In certain embodiments, the methods include assessing citrullination at one or more citrullination sites on a protein or peptide fragment thereof present in a biological sample.

The application discloses a method for constructing a model for recognizing mussel adhesive proteins, and belongs to the technical field of bioinformatics, and specifically comprises the following steps: inputting an amino acid sequence of a target protein, obtaining standard electromagnetic response waveforms of each amino acid residue in a variety of non-aqueous solvent environments, and sorting to form an initial electromagnetic fingerprint; polypeptide fragment fingerprints are generated through sliding window cutting, shared frequency components of each fragment waveform are extracted, and characteristic sequences are formed by sorting according to intensity; local patterns and context dependencies of the sequences are extracted through an encoder network, and a context vector is output; a decoder network maps the vector into a fixed-dimension embedding representation; known protein sequences with or without adhesive functions are used as training samples, the above-mentioned processing is performed on each sample to obtain a set of embedding representations, a binary classification model is trained, and a recognition model is obtained. The application realizes function recognition by using electromagnetic response characteristics of proteins in non-aqueous environments.

Convergent pathways for the preparation of a peptide by solid phase peptide synthesis or liquid phase peptide synthesis, as well as peptide fragments suitable for use in such pathways, are provided. The convergent pathways may be utilized for the synthesis of agonists of the glucagon-like peptide 1 receptor (GLP-1R) such as the peptide component of maridebart cafraglutide.

Method for functionalizing a solid support with a peptide conjugate. The present invention relates to a method for functionalizing a solid support with a peptide conjugate comprising a benzophenone anchoring head, a spacer arm, and a peptide fragment. It also relates to a solid support obtainable by a functionalization method according to the invention, as well as the use of the solid support according to the invention.

Provided herein are polynucleic acids and expression vectors for the expression and secretion of angiotensin peptide fragments (e.g., angiotensin-(1-7)) in probiotic bacteria. Provided herein are also probiotic compositions that enable efficient, cost-effective and patient friendly oral therapeutics for treating diverse pathological conditions that involve the renin-angiotensin system (RAS), e.g., pulmonary hypertension, diabetes, diabetic complications, cardiovascular diseases, and ocular inflammatory and neurodegenerative diseases.

Peptide fragments of Amuc_1100* and uses thereof are disclosed. The peptides are shown to be ligands that activate TLR2 and are useful in the treatment of obesity and related diseases or disorders. The peptides of the invention are further useful in the treatment of small intestinal cancer, in the promotion of immune responses, and in intestinal epithelial barrier dysfunction.

This invention relates to the field of peptide drug preparation techniques, specifically disclosing a method for the hydrophobic tag-assisted liquid-phase synthesis of retatrutide. The retatrutide preparation method includes the following steps: synthesizing two hydrophobic tags, TAG1 and TAG2; dividing retatrutide into six fragments and linking each fragment to a TAG; wherein the C-terminal amino group of TAG2 can be directly retained after deprotection; the peptide fragments obtained during synthesis can be purified by acetonitrile slurrying; the main chain of retatrutide is obtained by end-to-end ligation, followed by the ligation of side chains to obtain fully protected retatrutide; finally, deprotection and removal of the hydrophobic tag are performed to obtain retatrutide. The preparation method of this invention uses readily available starting materials, and the reaction operations and separation / extraction processes in each step of the synthesis route are simple, the conditions are mild, the overall yield is high, and material costs are significantly reduced.

The application discloses an active peptide agonist of an insulin-like peptide receptor of Crassostrea gigas and a method for identifying and applying the same, and belongs to the field of bioactive peptides. The amino acid sequence of the active peptide is selected from RWFYVNRLGRF, FELQQYCGFR and APWKSVLKRMMV. The method for identifying the active peptide of the Crassostrea gigas comprises the following steps: protein three-dimensional structure modeling, determination of a secreted peptide fragment, molecular dynamics simulation, construction of a binding free energy landscape, and screening of a candidate active peptide. The active peptide agonist significantly activates the insulin-like peptide receptor of the Crassostrea gigas, enhances the expression of a downstream channel mediated by the insulin-like peptide receptor, and promotes the metabolism and growth of the Crassostrea gigas.

Provided are crystalline forms of peptide fragments, method of preparation thereof, and use thereof for preparing peptides. The present crystalline compounds may be employed as intermediates with improved purity and physical properties for peptide syntheses.

This invention relates generally to isolated monoclonal antibodies that binds to an epitope of the 10 kDa culture filtrate protein (CFP-10) or a peptide fragment thereof, and methods for using the same to detect Mycobacterium tuberculosis.

The present disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of nucleic acid vaccines comprising polynucleotide sequences encoding one or more proteins, polypeptides or peptides fragments or variants thereof of tumor-associated antigens for the prevention, alleviation and / or treatment of various and other diseases, disorders and / or conditions caused by tumor-associated antigens.

A preparation method of a dual-receptor agonist of GIP and GLP-1. The provided preparation method uses a protected polypeptide fragment containing an Aib amino acid residue to replace a single protected amino acid Aib, and in the overall preparation process, the method of first modifying the side chain of lysine and then connecting the main chain amino acid and the polypeptide fragment can effectively improve the condensation efficiency, reduce the generation of impurities, improve the product purity, more easily separate the pure product through HPLC purification, improve the yield of finished product, and at the same time make the whole reaction control process more simple, and reduce the overall production cost of the product.

Provided is a bispecific antibody targeting CD3 and a tumor target and a use of the bispecific antibody. The bispecific antibody comprises a first antigen binding region, a second antigen binding region, and an Fc portion; the Fc portion comprises a first Fc peptide fragment and a second Fc peptide fragment; the first antigen binding region comprises an scFv fragment and a binding protein or fragment thereof of a first molecule, the binding protein or fragment thereof of the first molecule is linked to the N-terminal of the scFv fragment, and the C-terminal of the scFv fragment is linked to the N-terminal of the first Fc peptide fragment; the second antigen binding region comprises a binding protein or fragment thereof of a second molecule, and the binding protein or the fragment thereof of the second molecule is linked to the N-terminal of the second Fc peptide fragment fragment; and the first molecule and the second molecule are the identical, and the scFv fragment has CD3 binding activity. The bispecific antibody has weak binding to T-cells, strong binding to tumor cells, good safety, high anticancer activity, and significant value for clinical use and drug development.

The application discloses a method for continuously and enzymatically synthesizing a fragment of retaspimautide, a micro-reaction system and a method for preparing immobilized enzymes, and belongs to the technical field of polypeptide synthesis. The method comprises fragment splitting, substrate preparation, continuous flow enzymatic coupling, online monitoring and purification. The micro-reaction system comprises raw material conveying, modular micro-reaction, online monitoring and other modules, and realizes continuous and automatic synthesis. The immobilized enzyme adopts macroporous silica gel as a carrier and is prepared through pretreatment, covalent binding and post-treatment. The application combines the advantages of continuous flow and enzymatic synthesis, improves the purity of the product to more than 95%, shortens the synthesis time, reduces the production cost, reduces environmental pollution, is easy to scale up, and solves the problems of low efficiency and poor purity in the prior art.

The application discloses an antibacterial peptide segment intercepted from a Stomoxys calcitrans IDGF4 protein and application of the antibacterial peptide segment in preparation of antibacterial drugs. The application screens short peptide fragments in different positions of the Stomoxys calcitrans IDGF4 protein, obtains three candidate peptides through chemical synthesis, and systematically evaluates antibacterial performances of the three candidate peptides. The antibacterial experiment results show that the short peptide with the amino acid sequence shown in SEQ ID No. 2 can effectively inhibit growth of salmonella and staphylococcus aureus at a concentration of 1 mg / mL, the antibacterial effect is confirmed in an antibacterial circle experiment, an enzyme label turbidimetry method and growth curve monitoring, and the short peptide shows stable and significant antibacterial activity, indicating that the peptide segment can be used as a new antibacterial molecule. The application provides a new candidate sequence for development of efficient and low drug resistance risk antibacterial peptides, and has application potential in preparation of clinical antibacterial drugs.

The application discloses two peptide segments derived from Cervus elaphus Linnaeus and application of the two peptide segments in promoting wound healing. Amino acid sequences of the two peptide segments are Gly-Ser-Phe-Pro-Trp-Gln-Ala-Lys (SEQ ID NO:1) and His-Ser-Trp-Ala-Val-Pro-Ser-Leu (SEQ ID NO:2) respectively. In-vitro experiments show that the two peptide segments can significantly promote proliferation and migration of human umbilical vein endothelial cells and mouse skin fibroblasts; in-vivo mouse acute wound model experiments prove that the two peptide segments can effectively accelerate the healing process of mouse acute wounds, have excellent biological activity of promoting acute skin wound healing, and have a good application prospect in development of drugs and functional products related to wound repair.